JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 43(2009) N 3 p. 403-409;
I.V. Pronina1,2, V.I. Loginov1, V.S. Prasolov2, E.A. Klimov3, D.S. Khodyrev1, T.P. Kazubskaya4, R.F. Gar\'kavtseva4, G.E. Sulimova3, E.A. Braga1

Altered expression of the SEMA3B gene in epithelial tumors

1Russian State Genetics Center GosNIIgenetika, Moscow, 117545, Russia
2Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia
3Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, 119991, Russia
4Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, 115478, Russia
Received - 2008-10-24; Accepted - 2008-11-12

Tumor-specific expression downregulation may be indicative of a gene\'s involvement in tumor suppression. For instance, SEMA3B mRNA levels are decreased in many cell lines of small-cell and non-small cell lung cancer, and SEMA3B was shown to suppress the growth of the NSCLC cell line NCI-H1299 and tumor formation in immunodeficient mice. In this work, SEMA3B expression levels were determined in epithelial tumors of different localizations. In cell lines of renal, breast, and ovarian cancer, SEMA3B mRNA levels were frequently (4/11, 36%) decreased as much as 10-250-fold according to semiquantitative RT-PCR assay. SEMA3B expression levels were also determined in primary tumor extracts of kidney, lung, breast, ovarian, and colorectal cancer. In clear cell renal cell carcinoma, SEMA3B expression was decreased 5-1000-fold in 25 of 51 extracts (49%) compared to 5/51 (10%) extracts with increased mRNA levels; the result was highly significant: P < 0.0001 by Fisher\'s exact test. SEMA3B was frequently downregulated in ovarian (5/16, 31% vs. 2/16, 12%) and colorectal cancer (6/11, 54% vs. 2/11, 18%). These results suggest that SEMA3B is involved in the suppression of kidney, ovarian, and colon tumor growth.

chromosome 3, SEMA3B gene, gene expression, tumor cell lines, clear cell renal cell carcinoma, small cell and non-small cell lung carcinoma, breast carcinoma, ovarian carcinoma, colorectal carcinoma



JMB-FOOTER RAS-JOURNALS